Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses

The clinical performance of tricuspid valve replacement with bioprostheses and mechanical prostheses was assessed in a series of 5,489 total valve replacement operations performed from 1975 to 1992. There were 97 (1.8%) tricuspid valve replacements in 94 patients (16 men, 78 women) with a mean age o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Annals of thoracic surgery 1995-08, Vol.60 (2 Suppl), p.S470-S474
Hauptverfasser: Ian Munro, A., Eric Jamieson, W.R., Frank, G., Tyers, O., Germann, Eva
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S474
container_issue 2 Suppl
container_start_page S470
container_title The Annals of thoracic surgery
container_volume 60
creator Ian Munro, A.
Eric Jamieson, W.R.
Frank, G.
Tyers, O.
Germann, Eva
description The clinical performance of tricuspid valve replacement with bioprostheses and mechanical prostheses was assessed in a series of 5,489 total valve replacement operations performed from 1975 to 1992. There were 97 (1.8%) tricuspid valve replacements in 94 patients (16 men, 78 women) with a mean age of 55.4 ± 13.8 years. Bioprostheses (mean patient age, 55.9 ± 14.1 years) were used in 83 operations and mechanical prostheses (mean patient age, 52.1 ± 11.9 years) were used in 14 operations. There were 30 isolated tricuspid valve replacements and 67 tricuspid valve replacements incorporated in multiple valve replacements. The total cumulative follow-up was 360 patient-years (bioprostheses, 321 years; mechanical prostheses, 39 years) (96.8% complete). The mean follow-up was 3.7 years (bioprostheses, 3.9 years; mechanical prostheses, 2.8 years) (p = not significant). The early mortality was 14.4% (bioprostheses, 14.5%; mechanical prostheses, 14.3%) (p = not significant) (isolated replacement, 13.3%; multiple replacement, 14.9%). The late mortality was 9.2% per patient-year (isolated replacement, 12.2% per patient-year; multiple replacement, 7.9% per patient-year). The freedom from structural valve deterioration at 5 and 7 years was 100% for mechanical prostheses and 97.1% ± 2.9% for bioprostheses (p = not significant). For isolated tricuspid valve replacement, the freedom from structural valve deterioration for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). For the mechanical prostheses, the freedom was 100%. The freedom from valve-related reoperation for mechanical prostheses was 86.7% ± 12.4% at 5 and 7 years; for bioprostheses, it was 97.1% ± 2.9% at 5 years and 92.5% ± 5.2% at 7 years (p = not significant). There was one reoperation among the isolated replacements with bioprostheses (one of four), and freedom from reoperation for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). With multiple tricuspid valve replacement, the freedom from reoperation for mechanical prostheses was 84.6% ± 14.2% at 5 and 7 years; for bioprostheses, it was 100% at 5 years and 93.8% ± 6.1% at 7 years (p = not significant). Thrombosis was different (p < 0.05): for overall tricuspid valve replacement, the freedom from thrombosis for mechanical prostheses was 90.9% ± 8.7% at 5 and 7 years and for bioprostheses, it was 100%. In the tricuspid valve multiple replacement group, the freedom from thrombosis for mechanical prost
doi_str_mv 10.1016/0003-4975(95)00271-L
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77458212</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>000349759500271L</els_id><sourcerecordid>77458212</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-125ad02695f1b91f8c8afbb1ec51dfee59fa8f3db046e59bd3e66a65f9fa1dfd3</originalsourceid><addsrcrecordid>eNp9kMtKxDAUhoMo4zj6BgpdiS6qSdqkrQtBBm9Q0MW4DmlywkR6M2kLvr0ZZxh3rg7n_P-5fQidE3xDMOG3GOMkTouMXRXsGmOakbg8QHPCGI05ZcUhmu8tx-jE-8-Q0iDP0CzjKacEz1G5claNvrc6mmQ9QeSgr6WCBtrhLnrvnLItRJXtetf5YQ0efCRbHTWg1rK1StbRn3KKjoysPZzt4gJ9PD2uli9x-fb8unwoY5WwbIgJZVJjygtmSFUQk6tcmqoioBjRBoAVRuYm0RVOeUgqnQDnkjMT6sGgkwW63M4Nq79G8INorFdQ17KFbvQiy1KWU0KDMd0aVbjROzCid7aR7lsQLDYQxYaQ2BASBRO_EEUZ2i5288eqAb1v2lEL-v1Wh_DkZMEJryy0CrR1oAahO_v_gh8804Mi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77458212</pqid></control><display><type>article</type><title>Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via ScienceDirect (Elsevier)</source><source>Alma/SFX Local Collection</source><creator>Ian Munro, A. ; Eric Jamieson, W.R. ; Frank, G. ; Tyers, O. ; Germann, Eva</creator><creatorcontrib>Ian Munro, A. ; Eric Jamieson, W.R. ; Frank, G. ; Tyers, O. ; Germann, Eva</creatorcontrib><description>The clinical performance of tricuspid valve replacement with bioprostheses and mechanical prostheses was assessed in a series of 5,489 total valve replacement operations performed from 1975 to 1992. There were 97 (1.8%) tricuspid valve replacements in 94 patients (16 men, 78 women) with a mean age of 55.4 ± 13.8 years. Bioprostheses (mean patient age, 55.9 ± 14.1 years) were used in 83 operations and mechanical prostheses (mean patient age, 52.1 ± 11.9 years) were used in 14 operations. There were 30 isolated tricuspid valve replacements and 67 tricuspid valve replacements incorporated in multiple valve replacements. The total cumulative follow-up was 360 patient-years (bioprostheses, 321 years; mechanical prostheses, 39 years) (96.8% complete). The mean follow-up was 3.7 years (bioprostheses, 3.9 years; mechanical prostheses, 2.8 years) (p = not significant). The early mortality was 14.4% (bioprostheses, 14.5%; mechanical prostheses, 14.3%) (p = not significant) (isolated replacement, 13.3%; multiple replacement, 14.9%). The late mortality was 9.2% per patient-year (isolated replacement, 12.2% per patient-year; multiple replacement, 7.9% per patient-year). The freedom from structural valve deterioration at 5 and 7 years was 100% for mechanical prostheses and 97.1% ± 2.9% for bioprostheses (p = not significant). For isolated tricuspid valve replacement, the freedom from structural valve deterioration for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). For the mechanical prostheses, the freedom was 100%. The freedom from valve-related reoperation for mechanical prostheses was 86.7% ± 12.4% at 5 and 7 years; for bioprostheses, it was 97.1% ± 2.9% at 5 years and 92.5% ± 5.2% at 7 years (p = not significant). There was one reoperation among the isolated replacements with bioprostheses (one of four), and freedom from reoperation for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). With multiple tricuspid valve replacement, the freedom from reoperation for mechanical prostheses was 84.6% ± 14.2% at 5 and 7 years; for bioprostheses, it was 100% at 5 years and 93.8% ± 6.1% at 7 years (p = not significant). Thrombosis was different (p &lt; 0.05): for overall tricuspid valve replacement, the freedom from thrombosis for mechanical prostheses was 90.9% ± 8.7% at 5 and 7 years and for bioprostheses, it was 100%. In the tricuspid valve multiple replacement group, the freedom from thrombosis for mechanical prostheses was 88.9% ± 10.5% at 5 and 7 years and for bioprostheses, it was 100% at both times (p = not significant). Tricuspid valve replacement carries a high early and late mortality rate. Bioprostheses are recommended because of the low rate of structural valve deterioration and avoidance of thrombosis.</description><identifier>ISSN: 0003-4975</identifier><identifier>EISSN: 1552-6259</identifier><identifier>DOI: 10.1016/0003-4975(95)00271-L</identifier><identifier>PMID: 7646210</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Actuarial Analysis ; Bioprosthesis - adverse effects ; Bioprosthesis - mortality ; Female ; Heart Valve Prosthesis - adverse effects ; Heart Valve Prosthesis - mortality ; Humans ; Male ; Middle Aged ; Reoperation ; Survival Rate ; Thrombosis - etiology ; Tricuspid Valve - surgery</subject><ispartof>The Annals of thoracic surgery, 1995-08, Vol.60 (2 Suppl), p.S470-S474</ispartof><rights>1995</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-125ad02695f1b91f8c8afbb1ec51dfee59fa8f3db046e59bd3e66a65f9fa1dfd3</citedby><cites>FETCH-LOGICAL-c357t-125ad02695f1b91f8c8afbb1ec51dfee59fa8f3db046e59bd3e66a65f9fa1dfd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0003-4975(95)00271-L$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7646210$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ian Munro, A.</creatorcontrib><creatorcontrib>Eric Jamieson, W.R.</creatorcontrib><creatorcontrib>Frank, G.</creatorcontrib><creatorcontrib>Tyers, O.</creatorcontrib><creatorcontrib>Germann, Eva</creatorcontrib><title>Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses</title><title>The Annals of thoracic surgery</title><addtitle>Ann Thorac Surg</addtitle><description>The clinical performance of tricuspid valve replacement with bioprostheses and mechanical prostheses was assessed in a series of 5,489 total valve replacement operations performed from 1975 to 1992. There were 97 (1.8%) tricuspid valve replacements in 94 patients (16 men, 78 women) with a mean age of 55.4 ± 13.8 years. Bioprostheses (mean patient age, 55.9 ± 14.1 years) were used in 83 operations and mechanical prostheses (mean patient age, 52.1 ± 11.9 years) were used in 14 operations. There were 30 isolated tricuspid valve replacements and 67 tricuspid valve replacements incorporated in multiple valve replacements. The total cumulative follow-up was 360 patient-years (bioprostheses, 321 years; mechanical prostheses, 39 years) (96.8% complete). The mean follow-up was 3.7 years (bioprostheses, 3.9 years; mechanical prostheses, 2.8 years) (p = not significant). The early mortality was 14.4% (bioprostheses, 14.5%; mechanical prostheses, 14.3%) (p = not significant) (isolated replacement, 13.3%; multiple replacement, 14.9%). The late mortality was 9.2% per patient-year (isolated replacement, 12.2% per patient-year; multiple replacement, 7.9% per patient-year). The freedom from structural valve deterioration at 5 and 7 years was 100% for mechanical prostheses and 97.1% ± 2.9% for bioprostheses (p = not significant). For isolated tricuspid valve replacement, the freedom from structural valve deterioration for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). For the mechanical prostheses, the freedom was 100%. The freedom from valve-related reoperation for mechanical prostheses was 86.7% ± 12.4% at 5 and 7 years; for bioprostheses, it was 97.1% ± 2.9% at 5 years and 92.5% ± 5.2% at 7 years (p = not significant). There was one reoperation among the isolated replacements with bioprostheses (one of four), and freedom from reoperation for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). With multiple tricuspid valve replacement, the freedom from reoperation for mechanical prostheses was 84.6% ± 14.2% at 5 and 7 years; for bioprostheses, it was 100% at 5 years and 93.8% ± 6.1% at 7 years (p = not significant). Thrombosis was different (p &lt; 0.05): for overall tricuspid valve replacement, the freedom from thrombosis for mechanical prostheses was 90.9% ± 8.7% at 5 and 7 years and for bioprostheses, it was 100%. In the tricuspid valve multiple replacement group, the freedom from thrombosis for mechanical prostheses was 88.9% ± 10.5% at 5 and 7 years and for bioprostheses, it was 100% at both times (p = not significant). Tricuspid valve replacement carries a high early and late mortality rate. Bioprostheses are recommended because of the low rate of structural valve deterioration and avoidance of thrombosis.</description><subject>Actuarial Analysis</subject><subject>Bioprosthesis - adverse effects</subject><subject>Bioprosthesis - mortality</subject><subject>Female</subject><subject>Heart Valve Prosthesis - adverse effects</subject><subject>Heart Valve Prosthesis - mortality</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Reoperation</subject><subject>Survival Rate</subject><subject>Thrombosis - etiology</subject><subject>Tricuspid Valve - surgery</subject><issn>0003-4975</issn><issn>1552-6259</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKxDAUhoMo4zj6BgpdiS6qSdqkrQtBBm9Q0MW4DmlywkR6M2kLvr0ZZxh3rg7n_P-5fQidE3xDMOG3GOMkTouMXRXsGmOakbg8QHPCGI05ZcUhmu8tx-jE-8-Q0iDP0CzjKacEz1G5claNvrc6mmQ9QeSgr6WCBtrhLnrvnLItRJXtetf5YQ0efCRbHTWg1rK1StbRn3KKjoysPZzt4gJ9PD2uli9x-fb8unwoY5WwbIgJZVJjygtmSFUQk6tcmqoioBjRBoAVRuYm0RVOeUgqnQDnkjMT6sGgkwW63M4Nq79G8INorFdQ17KFbvQiy1KWU0KDMd0aVbjROzCid7aR7lsQLDYQxYaQ2BASBRO_EEUZ2i5288eqAb1v2lEL-v1Wh_DkZMEJryy0CrR1oAahO_v_gh8804Mi</recordid><startdate>19950801</startdate><enddate>19950801</enddate><creator>Ian Munro, A.</creator><creator>Eric Jamieson, W.R.</creator><creator>Frank, G.</creator><creator>Tyers, O.</creator><creator>Germann, Eva</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950801</creationdate><title>Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses</title><author>Ian Munro, A. ; Eric Jamieson, W.R. ; Frank, G. ; Tyers, O. ; Germann, Eva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-125ad02695f1b91f8c8afbb1ec51dfee59fa8f3db046e59bd3e66a65f9fa1dfd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Actuarial Analysis</topic><topic>Bioprosthesis - adverse effects</topic><topic>Bioprosthesis - mortality</topic><topic>Female</topic><topic>Heart Valve Prosthesis - adverse effects</topic><topic>Heart Valve Prosthesis - mortality</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Reoperation</topic><topic>Survival Rate</topic><topic>Thrombosis - etiology</topic><topic>Tricuspid Valve - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ian Munro, A.</creatorcontrib><creatorcontrib>Eric Jamieson, W.R.</creatorcontrib><creatorcontrib>Frank, G.</creatorcontrib><creatorcontrib>Tyers, O.</creatorcontrib><creatorcontrib>Germann, Eva</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of thoracic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ian Munro, A.</au><au>Eric Jamieson, W.R.</au><au>Frank, G.</au><au>Tyers, O.</au><au>Germann, Eva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses</atitle><jtitle>The Annals of thoracic surgery</jtitle><addtitle>Ann Thorac Surg</addtitle><date>1995-08-01</date><risdate>1995</risdate><volume>60</volume><issue>2 Suppl</issue><spage>S470</spage><epage>S474</epage><pages>S470-S474</pages><issn>0003-4975</issn><eissn>1552-6259</eissn><abstract>The clinical performance of tricuspid valve replacement with bioprostheses and mechanical prostheses was assessed in a series of 5,489 total valve replacement operations performed from 1975 to 1992. There were 97 (1.8%) tricuspid valve replacements in 94 patients (16 men, 78 women) with a mean age of 55.4 ± 13.8 years. Bioprostheses (mean patient age, 55.9 ± 14.1 years) were used in 83 operations and mechanical prostheses (mean patient age, 52.1 ± 11.9 years) were used in 14 operations. There were 30 isolated tricuspid valve replacements and 67 tricuspid valve replacements incorporated in multiple valve replacements. The total cumulative follow-up was 360 patient-years (bioprostheses, 321 years; mechanical prostheses, 39 years) (96.8% complete). The mean follow-up was 3.7 years (bioprostheses, 3.9 years; mechanical prostheses, 2.8 years) (p = not significant). The early mortality was 14.4% (bioprostheses, 14.5%; mechanical prostheses, 14.3%) (p = not significant) (isolated replacement, 13.3%; multiple replacement, 14.9%). The late mortality was 9.2% per patient-year (isolated replacement, 12.2% per patient-year; multiple replacement, 7.9% per patient-year). The freedom from structural valve deterioration at 5 and 7 years was 100% for mechanical prostheses and 97.1% ± 2.9% for bioprostheses (p = not significant). For isolated tricuspid valve replacement, the freedom from structural valve deterioration for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). For the mechanical prostheses, the freedom was 100%. The freedom from valve-related reoperation for mechanical prostheses was 86.7% ± 12.4% at 5 and 7 years; for bioprostheses, it was 97.1% ± 2.9% at 5 years and 92.5% ± 5.2% at 7 years (p = not significant). There was one reoperation among the isolated replacements with bioprostheses (one of four), and freedom from reoperation for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). With multiple tricuspid valve replacement, the freedom from reoperation for mechanical prostheses was 84.6% ± 14.2% at 5 and 7 years; for bioprostheses, it was 100% at 5 years and 93.8% ± 6.1% at 7 years (p = not significant). Thrombosis was different (p &lt; 0.05): for overall tricuspid valve replacement, the freedom from thrombosis for mechanical prostheses was 90.9% ± 8.7% at 5 and 7 years and for bioprostheses, it was 100%. In the tricuspid valve multiple replacement group, the freedom from thrombosis for mechanical prostheses was 88.9% ± 10.5% at 5 and 7 years and for bioprostheses, it was 100% at both times (p = not significant). Tricuspid valve replacement carries a high early and late mortality rate. Bioprostheses are recommended because of the low rate of structural valve deterioration and avoidance of thrombosis.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>7646210</pmid><doi>10.1016/0003-4975(95)00271-L</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4975
ispartof The Annals of thoracic surgery, 1995-08, Vol.60 (2 Suppl), p.S470-S474
issn 0003-4975
1552-6259
language eng
recordid cdi_proquest_miscellaneous_77458212
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via ScienceDirect (Elsevier); Alma/SFX Local Collection
subjects Actuarial Analysis
Bioprosthesis - adverse effects
Bioprosthesis - mortality
Female
Heart Valve Prosthesis - adverse effects
Heart Valve Prosthesis - mortality
Humans
Male
Middle Aged
Reoperation
Survival Rate
Thrombosis - etiology
Tricuspid Valve - surgery
title Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T08%3A23%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tricuspid%20valve%20replacement:%20Porcine%20bioprostheses%20and%20mechanical%20prostheses&rft.jtitle=The%20Annals%20of%20thoracic%20surgery&rft.au=Ian%20Munro,%20A.&rft.date=1995-08-01&rft.volume=60&rft.issue=2%20Suppl&rft.spage=S470&rft.epage=S474&rft.pages=S470-S474&rft.issn=0003-4975&rft.eissn=1552-6259&rft_id=info:doi/10.1016/0003-4975(95)00271-L&rft_dat=%3Cproquest_cross%3E77458212%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77458212&rft_id=info:pmid/7646210&rft_els_id=000349759500271L&rfr_iscdi=true